The Omega-3 Index: What 8% Means and Why Most Adults Don't Know Their Number

The Omega-3 Index — the proportion of EPA and DHA in red blood cell membranes — is one of the strongest individual predictors of cardiovascular mortality in the published epidemiology. Adults with an Omega-3 Index below 4 percent have markedly higher rates of sudden cardiac death than adults above 8 percent. Cognitive aging trajectories, inflammatory markers, and even all-cause mortality track with the Omega-3 Index across multiple cohort studies. And yet roughly 95 percent of US adults have never had it measured.

The marker was developed by William Harris (Sanford Research) and Clemens von Schacky (University of Munich) in the early 2000s, and the literature that's accumulated since has put the Omega-3 Index in the same category as apoB and Lp(a) — biomarkers that meaningfully change cardiovascular risk stratification but aren't on the standard panel most physicians order. Peter Attia routinely orders it. Casey Means and the Levels team include it in their longevity protocol framework. Rhonda Patrick has written extensively about it.

The Omega-3 Index is also one of the most actionable biomarkers in the entire longevity panel — supplementation with marine EPA + DHA at the right dose reliably moves the Index into the protective range within 3-6 months for most adults. What follows: the biology, the threshold targets that emerge from the cardiovascular and cognitive literature, the dose-response on supplementation, the form selection (fish oil vs algal omega-3 vs prescription EPA), and how to integrate Omega-3 Index data into the broader biomarker stack.

What the Omega-3 Index Actually Measures

The Omega-3 Index is the percentage of EPA (eicosapentaenoic acid) plus DHA (docosahexaenoic acid) in the fatty acid pool of red blood cell membranes, expressed as a percent of total membrane fatty acids. Red blood cells turn over approximately every 120 days, so the Index reflects long-term marine omega-3 status — not what you ate yesterday, but what you've been eating for the past 3-4 months.

This is the key methodological insight that distinguishes the Omega-3 Index from serum or plasma omega-3 measurements. Plasma omega-3 fluctuates dramatically based on the most recent meal — a salmon dinner two hours before a blood draw produces a very different number than the same blood draw eight hours fasted. Red blood cell membrane composition is much more stable, and the Index correlates with multi-month dietary patterns rather than with the most recent meal.

Mechanistically, the Index matters because membrane EPA and DHA serve as substrates for the eicosanoid signaling pathways that regulate inflammation, platelet aggregation, and vascular tone. EPA derivatives (resolvins, protectins) actively resolve inflammation rather than just blunting it. DHA is the most abundant fatty acid in neural and retinal membranes — the brain itself is roughly 60 percent fat by dry weight, with DHA making up the bulk of structural neural membrane phospholipids. The Omega-3 Index, then, is simultaneously a cardiovascular marker, a neural-health marker, and an inflammation marker.

The Thresholds That Matter

The Harris and von Schacky reference framework, validated across multiple subsequent cohort studies, identifies three Omega-3 Index zones:

• Index < 4 percent — High risk. Markedly elevated rate of sudden cardiac death and cardiovascular events. The Physicians' Health Study cohort data established a roughly 10× higher rate of sudden cardiac death in the lowest Index quartile (below ~4 percent) versus the highest quartile (above ~8 percent). Most Americans fall in this zone.
• Index 4-8 percent — Intermediate. Cardiovascular risk is reduced but not minimized. The gradient between 4 and 8 percent is approximately linear — every percentage point increase produces measurable risk reduction.
• Index > 8 percent — Cardioprotective. The target zone for adults pursuing aggressive cardiovascular longevity. Below approximately 4 percent of the US population reaches this naturally without supplementation.

Population-level data from US National Health and Nutrition Examination Survey (NHANES) and from commercial testing services (Omega Quant, Function Health) consistently show that the average US adult Omega-3 Index sits between 4 and 5 percent — squarely in the intermediate-risk zone. Adults in Japan, who consume substantially more fish, average 9-10 percent. The Inuit cohort studies that originally drew researchers' attention to marine omega-3s found Index values above 12 percent and correspondingly low cardiovascular event rates.

The longevity-protocol target that emerges from this gradient is straightforward: get above 8 percent and stay there. The marginal gain from going above 10 percent is small relative to the gain from moving from 4 to 8 percent, but no adverse effects appear at the upper end of the achievable range.

What the Cardiovascular Literature Actually Shows

The omega-3 supplementation trials have produced a complicated picture — and the careful read of that picture explains why the Omega-3 Index, not the daily dose, is what matters.

The early omega-3 cardiovascular trials (GISSI-Prevenzione, JELIS) showed clear benefit at 1-2 g daily EPA + DHA in post-MI populations. The middle wave of trials (OMEGA, RISK & PREVENTION, VITAL) showed weaker or null effects, leading some to argue that omega-3 supplementation doesn't work. The careful read of the divergent results: the early trials enrolled populations with very low baseline Omega-3 Indices, where moderate supplementation produced large Index increases. The middle trials enrolled populations with already-moderate baseline Indices, where the same supplemental dose produced smaller Index increases and correspondingly smaller clinical effects.

The REDUCE-IT trial in 2019 reframed the field. Using a purified EPA preparation (icosapent ethyl) at 4 g daily in statin-treated adults with elevated triglycerides, REDUCE-IT showed a 25 percent reduction in major adverse cardiovascular events — a magnitude rivaling statins. The Mason et al. mechanistic work argues that high-dose EPA produces unique membrane and inflammatory effects beyond what mixed EPA + DHA at lower doses achieves. The clinical interpretation has bifurcated:

• For baseline cardiovascular risk reduction in healthy adults, the Omega-3 Index above 8 percent target (achieved with ~2 g daily mixed EPA + DHA in most adults) is the operational goal.
• For adults with elevated triglycerides on statin therapy, the REDUCE-IT framework supports high-dose purified EPA (icosapent ethyl, prescription) as a distinct intervention category.

The healthy-adult-longevity case rests on Omega-3 Index improvement, not on the prescription EPA trial. The supplementation approach for adults running a longevity protocol is the membrane-target approach, not the pharmacological approach.

The Cognitive Longevity Side

DHA is the most abundant long-chain omega-3 in the brain. The cognitive aging literature on omega-3 supplementation has been more consistent than the cardiovascular literature, particularly in adults with declining cognitive function at baseline.

The Quinn et al. 2010 ADCS trial in established Alzheimer's disease showed no benefit, which has been overinterpreted. Subsequent analyses of the LipiDiDiet and OmegAD trials, plus the cohort literature, show benefit at the prodromal stage and in adults with low baseline Omega-3 Index — exactly the pattern the cardiovascular trials showed. The Schaefer et al. Framingham analysis identified an inverse relationship between fish intake and dementia incidence that maps onto the Omega-3 Index distribution.

The integrated cognitive case: maintaining an Omega-3 Index above 8 percent is one component of the broader cognitive longevity protocol the FINGER trial validated. Not the only component, not even the most important one — but a meaningful contributor that's directly modifiable with relatively low-cost intervention.

How to Move the Index — The Dose-Response

The published dose-response data shows that the Omega-3 Index rises in a roughly predictable pattern with supplementation:

• 0.5 g daily combined EPA + DHA — modest movement (typically +1-2 percentage points over 3-6 months in adults starting from low Index)
• 1 g daily combined EPA + DHA — moderate movement (typically +2-3 percentage points)
• 2 g daily combined EPA + DHA — reliable target-achievement dose for most adults to reach Index above 8 percent within 4-6 months
• 3-4 g daily combined EPA + DHA — faster Index movement, plus the high-EPA REDUCE-IT-style mechanism layer for adults with elevated triglycerides

The pragmatic protocol: test baseline Index, supplement at 2 g daily mixed EPA + DHA for 4 months, retest, adjust dose based on what the retest shows. Adults who started low may need to step up to 3 g. Adults whose baseline was already moderate may be able to step down to 1 g once the protective Index is reached. The data closes the loop only with retesting.

Form Selection — Fish Oil vs Algal vs Prescription

Three production formats dominate the consumer omega-3 market, with meaningfully different practical profiles:

Fish oil (most common). Sourced from small fatty fish (anchovy, sardine, mackerel) — the lower-trophic-level species that minimize mercury and PCB accumulation relative to larger predatory fish. Standard fish oil delivers EPA + DHA in a triglyceride or ethyl ester form. Quality varies dramatically by brand. The critical specifications: third-party-tested for oxidation (TOTOX value below 26 indicates fresh, non-rancid oil), heavy metal content below USP and IFOS limits, and EPA + DHA content per serving (not just "total omega-3," which can be inflated by including the less-active ALA from added vegetable oils). Cost: $0.20-$0.50 per gram EPA + DHA at premium brands.

Algal omega-3. EPA and DHA produced by cultured microalgae — the same algae that fish eat to produce their omega-3 content in the first place. Algal omega-3 is vegan, avoids the fish supply chain entirely, and has cleaner oxidation profiles in most testing because the production is more controlled. DHA content per gram tends to be higher than fish oil; EPA content per gram is typically lower. Cost: 2-3× fish oil at equivalent EPA + DHA. Best for vegan/vegetarian adults or those concerned about fish supply chain quality.

Prescription EPA (icosapent ethyl, Vascepa). Purified EPA only, in ethyl ester form, at therapeutic doses (4 g daily). Approved by the FDA for severe hypertriglyceridemia and cardiovascular risk reduction in specific populations. Significantly more expensive than supplements ($300-500/month retail) but typically insurance-covered for indicated patients. Outside the longevity-protocol scope for most healthy adults; relevant when triglycerides are elevated and a clinician is involved.

For the healthy-adult longevity protocol, the practical recommendation: premium fish oil at the third-party-tested specifications (TOTOX < 26, heavy metals below USP, EPA + DHA explicitly disclosed per serving). Algal omega-3 is the right choice for adults avoiding fish-derived products. Prescription EPA is a clinician-directed conversation for adults with established cardiovascular risk factors.

How to Get the Index Tested

The Omega-3 Index is not part of the standard lipid panel ordered at most primary care visits. Three paths to measurement:

Path 1: Function Health or comparable direct-to-consumer service. Function Health's advanced cardiovascular panel includes Omega-3 Index alongside apoB, Lp(a), hs-CRP, fasting insulin, and the broader marker set. No physician order needed. Results in 5-10 business days. Cost: ~$500 for the comprehensive panel, with Omega-3 Index as one of ~100 markers.

Path 2: Omega Quant direct test. The original commercial Omega-3 Index test, developed by William Harris (one of the marker's originators). Single-marker test by mail-in dried blood spot. Cost: ~$50 for the standalone Index test. Best for adults who already have a recent advanced cardiovascular panel and just want to track the Index over time.

Path 3: Request from your primary care physician. Most physicians will order the Omega-3 Index on request, particularly when framed around family history of cardiovascular disease. Some insurance plans cover the test, many do not. Out-of-pocket cost similar to Omega Quant.

The pragmatic measurement cadence: baseline test before starting supplementation, retest at 4-6 months after starting (to confirm the supplement is moving the Index as expected), then annually to track maintenance. The marker is stable enough that more frequent testing is rarely informative.

Integration With the Broader Biomarker Stack

The Omega-3 Index sits naturally alongside the other advanced cardiovascular markers in the longevity panel:

• apoB — the particle-count cardiovascular marker (covered in our deep dive). Pairs with Omega-3 Index — apoB drives particle-mediated atherosclerosis; Omega-3 Index modulates the inflammatory response to that process.
• Lp(a) — the genetic cardiovascular risk marker. Adults with elevated Lp(a) often pursue tighter Omega-3 Index targets as one of the compensation levers.
• hs-CRP — systemic inflammation marker. Higher Omega-3 Index correlates with lower hs-CRP across population studies.
• Fasting insulin and HOMA-IR — metabolic markers that pair with the Omega-3 Index's role in lipid metabolism.
• Homocysteine — modifiable cardiovascular and cognitive risk factor.
• CGM data — the daily metabolic context (covered in our CGM deep dive) that pairs with the quarterly biomarker snapshot.

The integrated panel is what Peter Attia, Casey Means, and Tom Dayspring operationalize as the cardiovascular-cognitive longevity framework. The full panel + the protocols for each marker live in Decode Your Biology. The wearables layer that pairs with the quarterly panel — CGM, HRV, VO2 max tracking — is covered in The Longevity Wearables Stack.

The Bottom Line

The Omega-3 Index is one of the few longevity biomarkers where:

• The published evidence base is strong across multiple decades and study designs
• The intervention is well-characterized at the dose-response level
• The intervention is low-cost and accessible (premium fish oil or algal omega-3 + a $50-500 test)
• The marker is highly responsive to behavior change within months, not years
• The cost of testing is modest relative to the risk-stratification value

For adults running a longevity protocol — particularly the cardiovascular and cognitive longevity facets — getting an Omega-3 Index baseline and intervening to reach the >8 percent target is one of the highest-leverage, lowest-cost decisions in the entire panel. The data has been clear for two decades. The intervention works. The retest closes the loop. Most adults haven't measured.

This article is part of the PureLongevity research library. Nothing here constitutes medical advice. Omega-3 supplementation interactions with anticoagulant therapy, gallbladder disease, and certain other clinical contexts require physician supervision. Always verify with a qualified clinician before changing a supplement protocol. PureLongevityToday may earn a commission from purchases made through links in this article.